Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

Liposomal Doxorubicin ◽

Case Series ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Case Series Report ◽

Metronomic Administration ◽

Series Report

Non Pegylated Liposomal Doxorubicin Beyond the First Line Treatment of Metastatic Breast Cancer Patients: A Retrospective Analysis

Annals of Oncology ◽

10.1016/s0923-7534(20)32919-7 ◽

2012 ◽

Vol 23 ◽

pp. ix128-ix129

Author(s):

S. Bernhard ◽

L. Mansi ◽

V. Nerich ◽

C.B. Villanueva ◽

E. Dobi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

First Line Treatment

Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study

Annals of Oncology ◽

10.1093/annonc/mdr024 ◽

2011 ◽

Vol 22 (12) ◽

pp. 2591-2596 ◽

Cited By ~ 20

Author(s):

M. Martín ◽

P. Sánchez-Rovira ◽

M. Muñoz ◽

J.M. Baena-Cañada ◽

J.R. Mel ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Cardiac Safety ◽

Her2 Positive

Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients

American Journal of Clinical Oncology ◽

10.1097/coc.0b013e3182005783 ◽

2012 ◽

Vol 35 (1) ◽

pp. 18-21 ◽

Cited By ~ 11

Author(s):

Jean-Philippe Jacquin ◽

Cyrus Chargari ◽

Julie Thorin ◽

Dominique Mille ◽

Adrien Mélis ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

European Journal of Cancer ◽

10.1016/j.ejca.2013.04.027 ◽

2013 ◽

Vol 49 (13) ◽

pp. 2806-2814 ◽

Cited By ~ 19

Author(s):

C. Falandry ◽

E. Brain ◽

M. Bonnefoy ◽

F. Mefti ◽

N. Jovenin ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-005-0116-2 ◽

2005 ◽

Vol 57 (5) ◽

pp. 615-623 ◽

Cited By ~ 17

Author(s):

Alessandra Fabi ◽

Gianluigi Ferretti ◽

Paola Papaldo ◽

Nello Salesi ◽

Mariangela Ciccarese ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: A valuable therapeutic option requiring caution

The Breast ◽

10.1016/j.breast.2010.05.008 ◽

2010 ◽

Vol 19 (6) ◽

pp. 549-550 ◽

Cited By ~ 5

Author(s):

Daniele Bernardi ◽

Domenico Errante ◽

Micaela Stefani ◽

Luigi Salvagno

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Therapeutic Option ◽

Metastatic Breast ◽

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

Oncology ◽

10.1159/000127411 ◽

2007 ◽

Vol 73 (3-4) ◽

pp. 210-214 ◽

Cited By ~ 8

Author(s):

J.E. Kurtz ◽

F. Rousseau ◽

N. Meyer ◽

T. Delozier ◽

D. Serin ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Line Chemotherapy

Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?

Annals of Oncology ◽

10.1093/annonc/mdi078 ◽

2005 ◽

Vol 16 (3) ◽

pp. 516-517 ◽

Cited By ~ 2

Author(s):

A. Fabi ◽

G. Ferretti ◽

N. Salesi ◽

P. Papaldo ◽

P. Carlini ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Her2 Overexpression ◽

Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

The Breast Journal ◽

10.1111/tbj.12975 ◽

2017 ◽

Vol 24 (4) ◽

pp. 473-479 ◽

Cited By ~ 1

Author(s):

Patricia Martin-Romano ◽

Iosune Baraibar ◽

Jaime Espinós ◽

Jairo Legaspi ◽

Jose M. López-Picazo ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Long Term Results ◽

Breast Cancer Patients ◽

Single Institution ◽

Heavily Pretreated

Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines

Journal of Chemotherapy ◽

10.1179/joc.2011.23.3.158 ◽

2011 ◽

Vol 23 (3) ◽

pp. 158-162 ◽

Cited By ~ 3

Author(s):

L. Livi ◽

I. Meattini ◽

V. Scotti ◽

C. De Luca Cardillo ◽

A. Galardi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Oral Vinorelbine ◽

Previously Treated